Rx Product News (April 2016)

Pharmacy TimesApril 2016 Respiratory Health
Volume 82
Issue 4

Read about the new Rx Products featured in April.

Pharmacyclics, Inc

Indication: The FDA has approved Imbruvica (ibrutinib), a kinase inhibitor, for treatment-naïve patients with chronic lymphocytic leukemia. For the recommended dosage, see the full prescribing information. Capsules should be taken orally with a glass of water and should not be opened, broken, or chewed. There are no contraindications for use.

Dosage Form: Capsules: 140 mg

For More Information: imbruvica.com

Dexilant SoluTabMarketed by: Takeda Pharmaceuticals

Indication: The FDA has approved Dexilant SoluTab (dexlansoprazole) for the following uses in adults:

  • Maintaining healing of erosive esophagitis and relief of heartburn
  • Treating heartburn associated with gastroesophageal reflux disease

For the recommended dosages, see the full prescribing information.

Dosage Form: Delayed-release orally disintegrating tablets: 30 mg

For More Information: takeda.us/products

Onzetra XsailMarketed by: Avanir Pharmaceuticals, Inc

Indication: The FDA has approved Onzetra Xsail (sumatriptan nasal powder), a serotonin 5-HT1B/1D receptor agonist (triptan), for acute treatment of migraine with or without aura in adults. The recommended dose is 22 mg, administered by use of 1 nosepiece (11 mg) in each nostril. The maximum dose in a 24-hour period should not exceed 2 doses (44 mg) separated by at least 2 hours.

Dosage Form: Capsule in disposable nosepiece: 11 mg sumatriptan as the succinate salt; for use with the Xsail breath-powered delivery device only

For More Information: onzetra.com

EmendMarketed by: Merck & Co, Inc

Indication: The FDA has approved Merck’s supplemental new drug application for Emend (single-dose fosaprepitant dimeglumine) for injection. Emend, a substance P/ neurokinin 1 receptor antagonist, is indicated for managing acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy, including high-dose cisplatin; nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy; and, in adults, prevention of postoperative nausea and vomiting.

Dosage Form: Injection: 150 mg in a single-use vial

For More Information: merck.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.